Theravance's strategic review with Andy Summers $TBPH

About this episode

Andrew Walker and Andy Summers discuss Theravance's strategic review and valuation following a failed Phase 3 trial.

In this episode of Yet Another Value Podcast, host Andrew Walker is joined by Andy Summers, CIO of Summers Value, to discuss Theravance (TBPH; disclosure: long). Both share their perspectives as shareholders while examining the company’s setup following a failed Phase 3 trial. They break down Theravance’s remaining asset, the COPD drug Yupelri, and its long-term royalty potential. The discussion covers the company’s balance sheet strength, cost reductions, and ongoing strategic review process. Andy outlines valuation assumptions, including U.S. royalties, China opportunity, and tax attributes, while also assessing potential buyers and deal dynamics. They also explore downside scenarios if a sale does not occur and why the situation presents an asymmetric risk-reward profile. ___________________________________________________ [00:00:00] Podcast introduction and sponsor mention [00:02:41] Overview of Theravance business model [00:05:02] Phase three failure stock decline [00:06:56] Activist involvement and ownership concentration [00:09:01] Strategic review process and acceleration [00:09:49] Breakdown of balance sheet and cash [00:12:49] Discussion on downside protection and…

People in this episode

Host: Andrew Walker

Guest: Andy Summers

Topics covered

• Theravance
• Yupelri
• strategic review
• valuation
• COPD drug
• investment analysis

Keywords

• Theravance
• Yupelri
• COPD
• valuation
• strategic review
• investment
• royalty potential

Mentioned in this episode

Organizations: Summers Value, Theravance, China

Products: Yupelri

More episodes of Yet Another Value Podcast

• Adam May on $ABVX's blowout data and subsequent stock crash · June 10, 2026 · 1h 13m
• Pershing Square Challenge 2026 finalists pitch Amadeus $AMS | the toll booth on global travel · June 4, 2026 · 52 min
• May 2026 Random Ramblings · May 31, 2026 · 28 min
• Pershing Square Challenge 2026 third place: Celsius $CELH · May 28, 2026 · 45 min
• Pershing Square Challenge 2026 runner-ups on Baker Hughes $BKR · May 25, 2026 · 46 min
• Pershing Square Challenge 2026 winners on DoorDash $DASH · May 22, 2026 · 57 min